A Kayvirus Distant Homolog of Staphylococcal Virulence Determinants and VISA Biomarker Is a Phage Lytic Enzyme.

Viruses
Aleksandra Głowacka-RutkowskaMałgorzata Łobocka

Abstract

Staphylococcal bacteriophages of the Kayvirus genus are candidates for therapeutic applications. One of their proteins, Tgl, is slightly similar to two staphylococcal virulence factors, secreted autolysins of lytic transglycosylase motifs IsaA and SceD. We show that Tgl is a lytic enzyme secreted by the bacterial transport system and localizes to cell peripheries like IsaA and SceD. It causes lysis of E. coli cells expressing the cloned tgl gene, but could be overproduced when depleted of signal peptide. S. aureus cells producing Tgl lysed in the presence of nisin, which mimics the action of phage holin. In vitro, Tgl protein was able to destroy S. aureus cell walls. The production of Tgl decreased S. aureus tolerance to vancomycin, unlike the production of SceD, which is associated with decreased sensitivity to vancomycin. In the genomes of kayviruses, the tgl gene is located a few genes away from the lysK gene, encoding the major endolysin. While lysK is a late phage gene, tgl can be transcribed by a host RNA polymerase, like phage early genes. Taken together, our data indicate that tgl belongs to the kayvirus lytic module and encodes an additional endolysin that can act in concert with LysK in cell lysis.

References

Jun 5, 1983·Journal of Molecular Biology·D Hanahan
Nov 26, 1993·International Journal of Food Microbiology·U SchillingerW H Holzapfel
Sep 1, 1997·Nucleic Acids Research·S F AltschulD J Lipman
Jan 1, 1997·Journal of Basic Microbiology·C M FranzW H Holzapfel
Jun 23, 2001·The Journal of Antimicrobial Chemotherapy·J M Andrews
Mar 14, 2003·Microbiology·Steve GrkovicRonald A Skurray
May 3, 2003·The Journal of Clinical Investigation·Franklin D Lowy
Jun 6, 2003·Applied and Environmental Microbiology·David A SchofieldMichael G Schmidt
May 6, 2004·Journal of Bacteriology·Imke WiedemannHans-Georg Sahl
Feb 8, 2005·Current Microbiology·Noriaki SakataToshiji Mukai
Mar 21, 2006·Biochemistry. Biokhimii︠a︡·K A MiroshnikovV V Mesyanzhinov
Sep 1, 2006·Applied Microbiology and Biotechnology·Oleg Paliy, Thusitha S Gunasekera
Mar 3, 2007·FEMS Immunology and Medical Microbiology·Noriaki Sakata, Toshiji Mukai
Aug 7, 2007·Journal of Bacteriology·Melanie R StapletonSimon J Foster
Oct 24, 2007·The Journal of Infectious Diseases·Mohammad RashelShigenobu Matsuzaki
Nov 6, 2007·Journal of Bacteriology·João Gil NascimentoMário Almeida Santos
Aug 30, 2008·FEMS Microbiology Letters·Stephen C BeckerDavid M Donovan
Jun 6, 2009·FEMS Microbiology Letters·Stephen C BeckerDavid M Donovan
Jun 23, 2009·Journal of Microbiological Methods·Katrijn BockstaelArthur Van Aerschot
Jun 23, 2009·Cellular and Molecular Life Sciences : CMLS·Ronny HellandAtle N Larsen
Jul 28, 2010·Proteomics·Annette DreisbachJan Maarten van Dijl
Apr 20, 2011·European Journal of Cell Biology·Liudmilla LapatsinaGary R Lewin

❮ Previous
Next ❯

Citations

Apr 22, 2021·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Małgorzata ŁobockaAndrzej Górski

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR
Fluorescence Microscopy
Bioscreen C
electrophoresis

Software Mentioned

HHpred
Tblastn
Blast
PSI
Blastp

Related Concepts

Related Feeds

Bacteriophage: Phage Therapy

Phage therapy uses bacterial viruses (bacteriophages) to treat bacterial infections and is widely being recognized as an alternative to antibiotics. Here is the latest research.